Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg

Why this Hong Kong tycoon’s family backed biotech firm ditches the city for Nasdaq listing

  • Investment sentiment has soured for Hong Kong-traded pharma and biotech stocks on China’s drug price reforms
  • Hang Seng Index has lost 13.6 per cent in 2018 versus Nasdaq’s 3.9 per cent drop
Topic |   Pharmaceuticals

TOP PICKS

Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg
READ FULL ARTICLE